Prime Medicine, Inc. Operating Lease, Weighted Average Discount Rate, Percent
Prime Medicine, Inc. (PRME) had Operating Lease, Weighted Average Discount Rate, Percent of 12.24% as of 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-03-03
- 2025-12-31: Operating Lease, Weighted Average Discount Rate, Percent 12.24%.
- 2024-12-31: Operating Lease, Weighted Average Discount Rate, Percent 12.83%.
- 2023-12-31: Operating Lease, Weighted Average Discount Rate, Percent 6.92%.
- 2022-12-31: Operating Lease, Weighted Average Discount Rate, Percent 4.92%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent |
|---|---|
| 2025-12-31 | 12.24% 10-K · filed 2026-03-03 |
| 2024-12-31 | 12.83% 10-K · filed 2026-03-03 |
| 2023-12-31 | 6.92% 10-K · filed 2025-02-28 |
| 2022-12-31 | 4.92% 10-K · filed 2024-03-01 |
| 2021-12-31 | 2.10% 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |